Application Review & Approval Process
As part of the Biosafety Program, the IBC reviews and approves all research involving recombinant DNA and biohazards and continued review of approved research projects. IBC approval of recombinant DNA and biohazardous research projects is effective for three years. PIs must complete an IBC Annual Renewal each year to continue work for up to three years after the initial approval. After three years, the application must be resubmitted and reviewed by the committee.
Research Involving the Following Requires IBC Approval
- Recombinant DNA and Synthetic Nucleic Acid Molecules
- Infectious Agents Biosafety Levels 2, 3 or 4.
- Hazardous Biological Agents including
- Viruses, Bacteria, Fungi, Parasites, Rickettsia, Prion, Human Primary or Cell LInes, Non Human Primate Primary or Cell Lines
- Other Potentially Infectious Materials:
- Other Human Material: Blood, Plasma, Serum, Unfixed Tissue, Organs, Unfixed Cells.
- Other Non-Human Primate Material: Blood, Plasma, Serum, Unfixed Tissue, Organs, Unfixed Cells.
- Sheep Material: Unfixed Tissue.
- Human Embryonic Stem Cells
- Inactivated Biological Samples
- Transgenic Animals and the Use of Biohazardous Materials in Animals
- Select Agents and Toxins
- Field studies with wild animals and animal tissues inherently infected or would be experimentally infected with BSL-2 or higher agents.
Note: BU considers Human Cell Lines to be BSL-2. E.coli K-12 strains are BSL-1 and as such do not require IBC approval.
Research Involving the Following May Require Additional Requirements
- Select Agents
- Agents with an Increased Risk to Cause Laboratory Acquired Infection (LAI)
- Attenuated Pathogens